Report Overview

2023

Base Year

2018-2023

Historical Year

2024-2032

Forecast Year

Ataxia Market Regional Analysis

The United States is anticipated to lead the ataxia market, owing to the presence of prominent biopharmaceutical companies, working to offer better treatment alternatives. In May 2023 , a Biohaven Ltd. announced the submission of a new drug application (NDA) for troriluzole to the United States FDA. The novel drug was designed to treat Spinocerebellar Ataxia Type 3 (SCA3) in patients.

 

Europe is also witnessing increased funding and investments by various sectors to accommodate the growing ataxia market demand. In January 2024 , Vico Therapeutics B.V., a clinical-stage genetic medication company based in the Netherlands, announced USD 60 million Series B financing. The funding is aimed to support the ongoing Phase 1/2a clinical trial of its intrathecally administered product VO659, designed to treat patients affected with spinocerebellar ataxia type 3 and type 1, among other neurological diseases.

 

Ataxia Market Report Snapshots

Ataxia Market Size

Ataxia Market Regional Analysis

Ataxia Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Outline the Scope

Key Questions Answered in the Report

The market attained a value of about USD 37.7 billion in 2023 driven by intensive research activities to develop effective drugs and therapies for ataxia patients across the 8 major markets.  

The market is anticipated to grow at a CAGR of 9.72% during the forecast period of 2024-2032, likely to reach a market value of USD 95.3 billion by 2032.

The growing availability of pharmacological and other treatment alternatives like stem cell therapies to patients suffering from ataxia are the major factors aiding the market demand.

The surge in drug approvals by health authorities is one of the major trends driving the ataxia market. In February 2023, the United States Food and Drug Administration (FDA) approved Skyclarys as the first authorized treatment for Friedreich’s ataxia.

There are different types of ataxias, including spinocerebellar ataxias, ataxia-telangiectasia, and episodic ataxia, among others (multiple system atrophy (MSA)).

Based on the age group, the market is segmented into adult, child, and geriatric.

Based on the dosage forms, the market is divided into solids and liquids, among others.

The services in the market include treatment and diagnosis.

Major end users in the market include hospitals, and clinics, among others.

The major regions of the market include the United States, Japan, China, EU-4, and the United Kingdom. EU-4 is segmented into Germany, France, Italy, and Spain.

Key players involved in the market are Novartis AG, Merck KGaA, Aurobindo Pharma, Pfizer Inc., Sanofi, Teva Pharmaceutical, Acorda Therapeutics, Viatris Inc., Design Therapeutics Inc., Lupin, Apotex Inc., Biohaven Pharmaceuticals, Amneal Pharmaceuticals LLC., Biovista, and Intrabio.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

Get Started
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

Get Started
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

Get Started
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

Get Started
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Gain insights to stay ahead and seize opportunities.

Get insights & trends for a competitive edge.

Track prices with detailed trend reports.

Analyse trade data for supply chain insights.

Leverage cost reports for smart savings

Enhance supply chain with partnerships.

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Request Brochure

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Get To Know Us

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

Our Services

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Markets We Cover
Back to top

We’re here to help answer any questions about our products and services.

Contact us

Get In Touch

Our Offices

Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

Quick Links

Who We Are

What We Offer

 

© 2024 Claight Corp. All Rights Reserved

$getforecastarray = array(); if (isset($ismapshow)) { $forecast_period_start = isset($forecast_period_start) ? $forecast_period_start : ''; if ($forecast_period_start != "") { $yearInc = 1; for ($startfrom = $forecast_period_start; $startfrom <= $forecast_period_end; $startfrom++) { $calculatFercastYear=calculateFutureValue(($getReportDetail['base_value']> 0) ? $getReportDetail['base_value'] : 100, $getReportDetail['cagr'], $yearInc); $getforecastarray[] = array('years' => "$startfrom", 'value' => $calculatFercastYear); $yearInc++; } } } $getforecastarrayJson = json_encode($getforecastarray); ?>